Sinphar Pharmaceutical Co Ltd

Sinphar Pharmaceutical Co Ltd maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.44, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.5, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if not managed effectively. In terms of profitability, Sinphar Pharmaceutical Co Ltd demonstrates a return on equity (ROE) of 10.62% and a return on assets (ROA) of 5.94%. These figures suggest the company is generating reasonable returns for its shareholders and effectively utilizing its assets. However, these metrics should be compared to the industry median to determine if they are above or below average. The company's revenue is primarily concentrated in its core pharmaceutical business, with no significant geographic diversification disclosed. This concentration could expose the company to regional economic or regulatory risks. The financial data does not provide a breakdown of revenue by geographic region, making it difficult to assess the extent of geographic exposure. Sinphar Pharmaceutical Co Ltd's growth trajectory is not explicitly detailed in the provided data, but the company's recent financial performance indicates a stable operating income and net income. The outlook for the current fiscal year and the next fiscal year is not provided, but the company's operating cash flow of 584,662,000 TWD and free cash flow of 222,171,000 TWD suggest it has the capacity to fund operations and potentially invest in growth opportunities. The risk assessment for Sinphar Pharmaceutical Co Ltd highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. However, the dilution risk is low, indicating that the company is not expected to issue a significant number of new shares in the near term. Recent events and filings for Sinphar Pharmaceutical Co Ltd are not detailed in the provided data. The company's financial performance and risk profile suggest it is a stable player in the pharmaceutical industry, but further information on recent strategic moves or regulatory changes would be necessary to fully assess its current position.